Manmeet Singh Ahluwalia: Stock and Other Ownersh

Manmeet Singh Ahluwalia:
Stock and Other Ownership Interests - CytoDyn; doctible; MedInnovate Advisors LLC; MimiVax
Honoraria - Elsevier; Peerview; Prime Education; Prime Oncology

Consulting or Advisory Role - Anheart Therapeutics; Apollomics; Bayer; Bugworks; Cairn Therapeutics; Caris Life Sciences; GlaxoSmithKline; InSightec; Janssen; Menarini Group; Modifi Bio; NH TherAguix; Nuvation Bio; Prelude Therapeutics; Pyramid Biosciences; SDP Oncology; ViewRay; Voyager Therapeutics; Xoft
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst); Seagen (Inst)"

* lost the link to what this was from & simply stumbled across him while random Cytodyn searching....
_____

" In 2009, following his fellowship, Dr. Ahluwalia joined Cleveland Clinic, working with the team in the Brain Tumor Neuro-oncologist Center, building clinical trials for patients with glioblastoma and other brain tumors.

DISCLOSURE @ the bottom:

Dr. Ahluwalia has received grants from...".....Cytodyn...."

https://ascopost.com/issues/august-10-2022/hi...ia-md-mba/
_____

He's of course affiliated with prominent Centers.

Can't say for sure the status of anything related to Cytodyn, buy @ his other Center, he's done addtl human glioblastoma trials. Not many Dr's like him I'd imagine.

so, maybe a future collab when we move into human trials...

Shall see....